Author Topic: End of Psychedelic Exploration  (Read 1058 times)


  • Administrator
  • Sr. Member

  • Offline
  • *****
  • 299
    • View Profile
    • Higher Intellect
End of Psychedelic Exploration
« on: February 15, 2017, 10:47:31 pm »
Subject: The End of Psychedelic Exploration - from Slothrop
Homage To: Shulgin's Psychedelic Publications

Alexander Shulgin is the worlds foremost developer and explorer of
psychedelic drugs.  He has been, and remains, a prolific writer.  His
publications provide a great introduction to the diverse world of
psychedelics, and provide and inspiration for psychedelic exploration.
However, Shulgin has informed me that the publishing of any
human data on new compounds had to stop abruptly with the enactment
of the Analogue Drug Bill in 1986.  This particular bit of obscenity
makes the generation, or even the attempted generation, of any altered
state of consciousness a felonious act.  The continuing publication of
experimental results in the medical and scientific literature is now
totally impossible.  For this reason I think it is worthwhile to
provide a complete list of his psychedelic publications.  They are
well referenced, and can lead to much other psychedelic literature.

Shulgin crossed the diamond with the pearl and gave birth to all forms of
light: "It is early morning now.  Slothrop's breath is white on the air.
He is just up from a dream.  Part I of a poem, with woodcuts accompanying
the text - a woman is attending a dog show which is also, in some way, a
stud service.  She has brought her Pekingese, a female with a sickeningly
cute name, Mimsy or Goo-Goo or something, here to be serviced.  She is
passing the time in a garden setting, with some other middle-class ladies
like herself, when from some enclosure nearby she hears the sound of
her bitch, coming.  The sound goes on and on for much longer than
seems appropriate, and she suddenly realizes that the sound is her own
voice, this interminable cry of dog-pleasure.  The others, politely, are
pretending not to notice.  She feels shame, but is helpless, driven now by
a need to go out and find other animal species to fuck.  She sucks the
penis of a multicolored mongrel who has tried to mount her in the
street.  Out in a barren field near a barbed-wire fence, winter fires across
the clouds, a tall horse compels her to kneel, passively, and kiss his
hooves.  Cats and minks, hyenas and rabbits, fuck her inside automo-
biles, lost at night in the forests, out beside a waterhole in the desert.

"As Part II begins, she has discovered she's pregnant.  Her husband, a
dumb, easygoing screen door salesman, makes an agreement with her:
her own promise is never stated, but in return, nine months from now,
he will take her where she wants to go.  So it is that close to the end of
her term he is out on the river, and American river, in a rowboat, hauling
on the oars, carrying her on a journey.  The key color in this section is

"Part III finds her at the bottom of the river.  She has drowned.  But all
forms of life fill her womb.  'Using her as mermaid' (line 7), they trans-
port her down through these green river-depths.  'It was down, and out
again./  Old Squalidozzi, ploughman of the deep,/  At the end of his
day's sowing/  Sees her verdigris belly among the weeds' (lines 10-13),
and brings her back up.  He is a classically-bearded Neptune figure with
an old serene face.  From out of her body streams a flood now of dif-
ferent creatures, octopuses, reindeer, kangaroos, 'Who can say all the
life/  That left her womb that day?'  Squalidozzi can only catch a
glimpse of the amazing spill as he bears her back toward the surface.
Above, it is a mild and sunlit green lake or pond, grassy at the banks,
shaded by willows.  Insects whine and hover.  The key color now is
green.  'And there as it broke to sun/  Her corpse found sleep in the
water/  And in the summer depths/  The creatures took their way/  Each
to its proper love/  In the height of afternoon/  As the peaceful river
went....'"  Pynchon (1973, p. 446-447)

For reprints of Shulgin's publications, write to:

Alexander T. Shulgin
1483 Shulgin Road
Lafayette, CA  94549

Be merciful.  He is out of many of the older papers, and probably doesn't
have reprints of the longer review articles.  Don't request reprints of
articles that you can get at the library.  After each article I have
included a number.  These are the numbers that Shulgin uses to reference
his papers.  If you include these it will make it easier for him to
locate them.  I have the references in troff format.  For those not
familiar with this format, I include a list of the format commands.

\fI     start italics
\fG     start greek
\fR     end italics or greek
\u      shift up half line, begin superscript or end subscript
\d      shift down half line, begin subscript or end superscript
\s+2    increase point size by two
\s-2    decrease point size by two
\*'     accent on preceding letter
\*:     umlaut on preceding letter

Pynchon, Thomas.  1973.  Gravity's Rainbow.  The Viking Press, N.Y.  Pp. 760.
Shulgin, A. T., S. Bunnell, and T. Sargent.  1961.  The psychotomimetic
properties of 3,4,5-trimethoxyamphetamine.  Nature 189: 10011-1012.  12
_____.  1963.  Psychotomimetic agents related to mescaline.  Experientia
19: 127.  19
_____.  1963.  Composition of the myristicin fraction from oil of nutmeg.
Nature 197: 379.  20
_____.  1963.  Concerning the pharmacology of nutmeg.  Mind 1: 299-302.  23
_____.  1964.  3-methoxy-4,5-methylenedioxy amphetamine, a new
psychotomimetic agent.  Nature 201: 1120-1121.  29
_____.  1964.  Psychotomimetic amphetamines: methoxy 3,4-dialkoxyamphetamines
Experientia 20: 366.  30
_____, and H. O. Kerlinger.  1964.  Isolation of methoxyeugenol and trans-
isoelemicin from oil of nutmeg.  Naturwissenschaften 15: 360-361.  31
_____.  1965.  Synthesis of the trimethoxyphenylpropenes.  Can. J. Chem.
43: 3437-3440.  43
_____.  1966.  Possible implication of myristicin as a psychotropic substance
Nature 210: 380-384.  45
_____.  1966.  The six trimethoxyphenylisopropylamines
(trimethoxyamphetamines).  J. Med. Chem. 9: 445-446.  46
_____, T. Sargent, and C. Naranjo.  1966.  Role of 3,4-dimethoxyphenethylamin
in schizophrenia.  Nature 212: 1606-1607.  48
_____, T. Sargent, and C. Naranjo.  1967.  The chemistry and psychopharmacolo
of nutmeg and of several related phenylisopropylamines.  \fIIn\fR D. H.
Efron [ed.]: Ethnopharmacologic search for psychoactive drugs.  U. S. Dept.
of H. E. W., Public Health Service Publication No. 1645.  Pp. 202-214.
Discussion: ibid. pp. 223-229.  49
_____, and T. Sargent.  1967.  Psychotropic phenylisopropylamines derived
from apiole and dillapiole.  Nature 215: 1494-1495.  50
Sargent, T. W., D. M. Israelstam, A. T. Shulgin, S. A. Landaw, and N. N.
Finley.  1967.  A note concerning the fate of the 4-methoxyl group in
3,4-dimethoxyphenethylamine (DMPEA).  Biochem. Biophys. Res. Commun.
29: 126-130.  52
Naranjo, C., A. T. Shulgin, and T. Sargent.  1967.  Evaluation of
3,4-methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy.
Med. Pharmacol. Exp. 17: 359-364.  53
Shulgin, A. T.  1968.  The ethyl homologs of 2,4,5-trimethoxyphenylisopropyl-
amine.  J. Med. Chem. 11: 186-187.  54
_____, T. Sargent, and C. Naranjo.  1969.  Structure activity relationships
of one-ring psychotomimetics.  Nature 221: 537-541.  57
_____.  1969.  Recent developments in cannabis chemistry.  J. Psyched. Drugs
2: 15-29.  58
_____.  1969.  Psychotomimetic agents related to the catecholamines.
J. Psyched. Drugs 2(2): 12-26.  59
_____.  1970.  Chemistry and structure-activity relationships of the
psychotomimetics.  \fIIn\fR: D. H. Efron [ed.].  Psychotomimetic Drugs.
Raven Press, New York.  Pp. 21-41.  60
_____.  1970.  The mode of action of psychotomimetic drugs; some qualitative
properties of the psychotomimetics.  Neur. Res. Prog. Bull. 8: 72-78.  61
_____.  1970.  4-alkyl-dialkoxy-\fGa\fR-methyl-phenethylamines and their
pharmacologically-acceptable salts.  U. S. Patent 3,547,999, issued Dec. 15,
1970.  63
_____, T. Sargent, and C. Naranjo.  1971.  4-bromo-2,5-dimethoxyphenyliso-
propylamine, a new centrally active amphetamine analog.  Pharmacology
5: 103-107.  64
_____.  1971.  Chemistry and sources.  \fIIn\fR: S. S. Epstein [ed].
Drugs of abuse: their genetic and other chronic nonpsychiatric hazards.
The MIT Press, Cambridge, Mass.  Pp 3-26.  65
_____.  1971.  Preliminary studies of the synthesis of nitrogen analogs
of \fGD\fR\u\s-21\s+2\d-THC.  Acta Pharm. Suec. 8: 680-681.  66
_____.  1972.  Hallucinogens, CNS stimulants, and cannabis.  \fIIn\fR:
S. J. Mule/*' and H. Brill [eds.]: Chemical and biological aspects of
drug dependence.  CRC Press, Cleveland, Ohio.  Pp. 163-175.  67
_____.  1973.  Stereospecific requirements for hallucinogenesis.
J. Pharm. Pharmac. 25: 271-272.  68
_____.  1973.  Mescaline: the chemistry and pharmacology of its analogs.
Lloydia 36: 46-58.  69
_____.  1973.  The narcotic pepper - the chemistry and pharmacology of
\fIPiper methysticum\fR and related species.  Bull. Narc. 25: 59-74.
Le poivre stupe\*'fiant - chemie et pharmacologie du \fIPiper methysticum\fR
et des espe\*'ces apparente\*'es.  Bull. Stupe\*'fiants 25: 61-77.  70
_____, T. Sargent, and C. Naranjo.  1973.  Animal pharmacology and human
psychopharmacology of 3-methoxy-4,5-methylenedioxyphenylisopropylamine
(MMDA).  Pharmacology 10: 12-18.  71
_____.  Drugs of abuse in the future.  Drug abuse in America Vol. 1.
pp. 209-236.  U.S.G.P.O. 5266-00004.  Reprinted: Clin. Tox. 8: 405-456.  72
Kalbhen, D. A., T. Sargent, A. T. Shulgin, G. Braun, H. Stauffer, N. Kusubov,
and M. L. Nohr.  1974.  Human pharmacodynamics of the psychodysleptic
4-bromo-2,5-dimethoxyphenylisopropylamine labelled with \u82\dBr.
IRCS (Int. Res. Comm. Sys.) 2: 1091.  73
Sargent, T., D. A. Kalbhen, A. T. Shulgin, H. Stauffer, and N. Kusubov.  1975
A potential new brain-scanning agent: 4-\u77\dBr-2,5-dimethoxyphenyliso-
propylamine (4-Br-DPIA).  J. Nucl. Med. 16: 243-245.  74
Shulgin, A. T., and M. F. Carter.  1975.  Centrally active phenethylamines.
Psychopharm. Commun. 1: 93-98.  75
Sargent, T., D. A. Kalbhen, A. T. Shulgin, G. Braun, H. Stauffer, and
N. Kusubov.  1975.  \fIIn vivo\fR human pharmacodynamics of the
psychodysleptic 4-Br-2,5-dimethoxyphenylisopropylamine labelled with
\u82\dBr or \u77\dBr.  Neuropharmacology 14: 165-174.  76
_____.  1975.  The chemical catalysis of altered states of consciousness.
Altered states of consciousness, current views and research problems.
The drug abuse council, Washington, D. C.  Pp. 123-134.  77
_____.  1975.  Drug use and anti-drug legislation.  The PharmChem
Newsletter 4 (#8).  79
_____, and D. C. Dyer.  1975.  Psychotomimetic phenylisopropylamines.  5.
4-alkyl-2,5-dimethoxyphenylisopropylamines.  J. Med. Chem. 18: 1201-1204.  80
_____, and C. Helisten.  1975.  Differentiation of PCP, TCP, and a
contaminating precursor PCC, by thin layer chromatography.  Microgram 8:
171-172.  81
Helisten, C., and A. T. Shulgin.  The detection of 1-piperidinodydlohexane-
carbonitrile contamination in illicit preparations of 1-(1-phenylcyclohexyl)
piperidine and 1-(1-(2-thienyl)cyclohexyl)piperidine.  J. Chrom. 117:
232-235.  82
Shulgin, A. T.  1976.  Psychotomimetic agents.  \fIIn\fR: M. Gordon [ed.]
Psychopharmacological agents, Vol. 4.  Academic Press, New York.
Pp. 59-146.  83
_____.  1976.  Abuse of the term "amphetamines".  Clin. Tox. 9: 351-352.  84
_____.  1976.  Profiles of psychedelic drugs.  1.  DMT.  J. Psychedelic
Drugs 8: 167-168.  85
_____.  1976.  Profiles of psychedelic drugs.  2.  TMA-2.  J. Psychedelic
Drugs 8: 169.  86
_____, and D. E. MacLean.  1976.  Illicit synthesis of phencyclidine (PCP)
and several of its analogs.  Clin. Tox. 9: 553-560.  87
Nichols, D. E., and A. T. Shulgin.  1976.  Sulfur analogs of psychotomimetic
amines.  J. Pharm. Sci. 65: 1554-1556.  89
Sargent, T., A. T. Shulgin, and N. Kusubov.  1976.  Quantitative
measurement of demethylation of \u14\dC-methoxyl labeled DMPEA and TMA-2
in rats.  Psychopharm. Commun. 2: 199-206.  90
Standridge, R. T., H. G. Howell, J. A. Gylys, R. A. Partyka, and A. T.
Shulgin.  1976.  Phenylalkylamines with potential psychotherapeutic utility.
1.  2-amino-1-(2,5,-dimethoxy-4-methylphenyl)butane.  J. Med. Chem.
19: 1400-1404.  91
_____.  1976.  Profiles of psychedelic drugs.  3.  MMDA.  J. Psychedelic
Drugs 8: 331.  92
_____.  1977.  Profiles of psychedelic drugs.  4.  Harmaline.  J. Psychedelic
Drugs 9: 79-80.  93
_____.  1977.  Profiles of psychedelic drugs.  5.  STP.  J. Psychedelic Drugs
9: 171-172.  94
Nichols, D. E., A. T. Shulgin, and D. C. Dyer.  1977.  Directional lipophilic
character in a series of psychotomimetic phenethylamine derivatives.  Life
Sciences 21: 569-576.  95
Jacob, P. III, G. Anderson III, C. K. Meshul, A. T. Shulgin, and N.
Castagnoli Jr.  1977.  Mononethylthio analogues of 1-(2,4,5-trimethoxyphenyl)
2-aminopropane.  J. Med. Chem. 20: 1235-1239.  96
White, T. J., D. Goodman, A. T. Shulgin, N. Castagnoli Jr., R. Lee, and
N. L. Petrakis.  1977.  Mutagenic activity of some centrally active aromatic
amines in \fISalmonella typhimurium\fR.  Mutation Research 56: 199-202.  97
Braun, U., A. T. Shulgin, G. Braun, and T. Sargent III.  1977.  Synthesis
and body distribution of several iodine-131 labeled centrally acting
drugs.  J. Med. Chem. 20: 1543-1546.  98
Sargent, T. III, T. F. Budinger, G. Braun, A. T. Shulgin, and U. Braun.
1978.  An iodated catecholamine congener for brain imaging and metabolic
studies.  J. Nucl. Med. 19: 71-76.  99
Shulgin, A. T.  1978.  Psychotomimetic drugs: structure-activity
relationships.  \fIIn\fR: L. L. Iversen, S. D. Iversen, and S. H. Snyder
[eds.], Handbook of psychopharmacology, Vol. 11.  Plenum Press, New
York.  Pp. 243-333.
Sargent, T. III, G. Braun, U. Braun, T. F. Budinger, and A. T. Shulgin.
1978.  Brain and retina uptake of a radio-iodine labeled psychotomimetic
in dog and monkey.  Commun. Psychopharm. 2: 1-10.  101
Braun, G., A. T. Shulgin, and T. Sargent III.  1978.  Synthesis of
\u123\dI-labelled 4-iodo-2,5-dimethoxyphenylisopropylamine.  J. Labelled
Comp. and Radiopharm. 14: 767-773.  102
Murdock, J. E., J. R. Patty, and A. T. Shulgin.  1978.  A novel illicit
amphetamine laboratory.  Microgram 11: 98-101.  103
Anderson, G. M. III, G. Braun, U. Braun, D. E. Nichols, and A. T. Shulgin.
1978.  Absolute configuration and psychotomimetic activity.  \fIIn\fR:
G. Barnett, M. Trsic, and R. Willette [eds.], QuaSAR Research Monograph 22.
N.I.D.A. Washington, D.C.  Pp. 8-15.  104
Braun, U., G. Braun, P. Jacob III, D. E. Nichols, and A. T. Shulgin.
Mescaline analogs: substitutions at the 4-position.  \fIIn\fR:
G. Barnett, M. Trsic, and R. Willette [eds.], QuaSAR Research Monograph 22.
N.I.D.A. Washington, D.C.  Pp. 27-37.  105
Partyka, R. A., R. T. Standridge, H. G. Howell, and A. T. Shulgin.  1978.
2-amino-1-(2,5-dimethoxyphenyl)butanes.  U.S. Patent 4,105,695, issued
Aug. 8, 1978.  106
Shulgin, A. T., and D. E. Nichols.  1978.  Characterization of three new
psychotomimetics.  \fIIn\fR: R. C. Stillman and R. E. Willette [eds.],
The psychopharmacology of hallucinogens.  Pergamon Press, New York.
Pp. 74-83.  107
Glennon, R. A., L. B. Kier, and A. T. Shulgin.  1979.  Molecular
connectivity analysis of hallucinogenic mescaline analogs.  J. Pharm.
Sci. 68: 906-907.  108
Shulgin, A. T.  1979.  Chemistry of phenethylamines related to mescaline.
J. Psychedelic Drugs 11: 41-52.  109
_____.  1979.  Profiles of psychedelic drugs.  6.  \fGa\fR,O-DMS.
J. Psychedelic Drugs 11: 247.  110
_____.  1979.  Profiles of psychedelic drugs.  7.  Mescaline.  J.
Psychedelic Drugs 11: 355.  111
Standridge, R. T., H. G. Howell, H. A. Tilson, J. H. Chamberlain, H. M.
Holava, J. A. Gylys, R. A. Partyka, and A. T. Shulgin.  1980.
Phenylalkylamines with potential psychotherapeutic utility.  2.  Nuclear
substituted 2-amino-1-phenylbutanes.  J. Med. Chem. 23: 154-162.  112
Braun, U., A. T. Shulgin, and G. Braun.  1980.  Centrally active
N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine
(3,4-methylenedioxyamphetamine).  J. Pharm. Sci. 69: 192-195.  113
Kantor, R. E., S. D. Dudlettes, and A. T. Shulgin.  1980.  5-methoxy-
\fGa\fR-methyltryptamine (\fGa\fR,O-dimethylserotonine) a hallucinogenic
homolog of serotonin.  Biol. Psychiat. 15: 349-352.  114
Shulgin, A. T.  1980.  Profiles of psychedelic drugs.  8.  psilocybin.
J. Psychedelic Drugs 12: 79.  115
Braun, U., A. T. Shulgin, and G. Braun.  1980.  Pru\*:fung auf
Aktivita\*:t und Analgesia von N-substituierten Analogen des Amphetamin-
Derivates 3,4-Methylendioxyphenylisopropylamin.  Arzneim. Forsch.
30: 825-830.  116
Shulgin, A. T.  1980.  Profiles of psychedelic drugs.  9.  LSD.
J. Psychedelic Drugs 12: 173-174.  117
_____.  1981.  Hallucinogens.  \fIIn\fR: M. E. Wolff [ed.], Burger's
medicinal chemistry.  Wiley & Co.  Pp. 1109-1137.
_____.  1981.  Profiles of psychedelic drugs.  10.  DOB.  J. Psychoactive
Drugs 13: 99.  119
_____, and M. F. Carter.  1981.  N,N-diisopropyltryptamine (DIPT) and
5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT).  Two orally active
tryptamine analogs with CNS activity.  Commun. Psychopharmacol.
4: 363-369.  120
Jacob, P., and A. T. Shulgin.  1981.  Sulfur analogues of psychotomimetic
agents.  Monothio analogues of mescaline and isomescaline.  J. Med. Chem.
24: 1348.  121
Domelsmith, L. N., T. A. Eaton, K. N. Houk, G. M. Anderson, R. A. Glennon,
A. T. Shulgin, N. Castagnoli, and P. A. Kollman.  1981.  Photoelectron
spectra of psychotropic drugs.  6.  Relationships between physical
properties and pharmacological actions of amphetamine analogues.
J. Med. Chem. 24: 1414.  122
Shulgin, A. T.  1981.  Chemistry of psychotomimetics.  \fIIn\fR:
F. Hoffmeister and G. Stille [eds.], Handbook of experimental pharmacology,
Vol. 55/III.  Springer-Verlag, Berlin Heidelberg.  Pp. 3-29.
_____.  1981.  Profiles of psychedelic drugs.  11.  Bufotenine.
J. Psychoactive Drugs 13: 389.  124
_____, and P. Jacob.  1982.  Potential misrepresentation of 3,4-methylene-
dioxyamphetamine (MDA).  A toxicological warning.  J. Anal. Tox. 6: 71.  127
_____, and P. Jacob.  1982.  1-(3,4-methylenedioxyphenyl)-3-aminobutane:
a potential toxicological problem.  J. Toxicol. - Clin. Toxicol. 19: 109.  12
Jacob, P., and A. T. Shulgin.  1983.  Sulfur analogues of psychotomimetic
agents.  2.  Analogues of (2,5-dimethoxy-4-methylphenyl)- and (2,5-
dimethoxy-4-ethylphenyl)-isopropylamine.  J. Med. Chem. 26: 746.  130
Shulgin, A. T.  1983.  Twenty years on an ever-changing quest.  \fIIn\fR:
L. Grinspoon and J. B. Bakalar [eds.], Psychedelic Reflections.  Human
Sciences Press, New York.  131
Sargent, T., A. T. Shulgin, and C. A. Mathis.  1982.  New iodinated
amphetamines by rapid synthesis for use as brain blood flow indicators.
J. Lab. Cmpds. and Radiopharm. 19: 1307.  132
Jacob, P., and A. T. Shulgin.  1984.  Sulfur analogues of psychotomimetic
agents.  3.  The ethyl homologues of mescaline and their monothio analogues.
J. Med. Chem. 27: 881-888.  133
Sargent, T., A. T. Shulgin, and C. A. Mathis.  1984.  Radiohalogen-labeled
imaging agents.  3.  Compounds for measurement of brain blood flow by
emission tomography.  J. Med. Chem. 27: 1071-1077.  135
Repke, D. B., D. B. Grotjahn, and A. T. Shulgin.  1985.  Psychotomimetic
N-methyl-N-isopropyltryptamines.  Effects of variation of aromatic
oxygen substituents.  J. Med. Chem. 28: 892.  136
Shulgin, A. T.  1985.  What is MDMA?  PharmChem Newsletter 14: 3
(May-June, #3).  137
Lemaire, D., P. Jacob, and A. T. Shulgin.  1985.  Ring substituted
beta-methoxyphenethylamines: a new class of psychotomimetic agents active
in man.  J. Pharm. Pharmacol. 37: 575.  138
Mathis, C. A., T. Sargent, and A. T. Shulgin.  1985.  Iodine-122 labeled
amphetamine derivatives with potential for PET brain blood-flow studies.
J. Nucl. Med. 26: 1295.  139
_____, _____, and _____.  1986.  Synthesis of 122-I and 125-I-labeled-
\fImeta\fR-dimethoxy-N,N-dimethyliodophenylisopropylamines.  J. Labelled
Comp. Radiopharm. 23: 115.  140
Shulgin, A. T., L. A. Shulgin, and P. Jacob.  1986.  A protocol for the
evaluation of new psychoactive drugs.  Methods and Findings in
Experimental and Clinical Pharmacology 8: 313.  141
Nichols, D. E., A. J. Hoffman, R. A. Oberlender, P. Jacob, and A. T.
Shulgin.  1986.  Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine:
representatives of a novel therapeutic class.  J. Med. Chem. 29: 2009.  143
Mathis, C. A., A. T. Shulgin, Y. Yano, and T. Sargent.  1986.  \u18\dF-
labelled N,N-dimethylamphetamine analogues for brain imaging studies.
Appl. Radiat. Isot. 37: 865.  144
Shulgin, A. T.  1986.  The background and chemistry of MDMA.  J. Psychoactive
Drugs 18: 291-304.  145
Sargent, T. W., A. T. Shulgin, and C. A. Mathis.  1987.  Rapid brain
scanning pharmaceutical.  U. S. Patent 4,647,446.  146
McKenna, D. J., C. A. Mathis, A. T. Shulgin, T. Sargent, and J. M. Saavedra.
1987.  Autoradiographic localization of binding sites for \u125\dI-DOI,
a new psychotomimetic radioligand, in the rat brain.  Eur. J. Pharmacol.
137: 289-290.  147
Shulgin, A. T.  1987.  The 'social-chemistry' of pharmacological discovery.
Social Pharmacology 1: 279-290.  148
_____.  1987.  Reference information on MDMA.  Analog 9: #4 (page 10).  149
_____.  1988.  DIPT: the distortion of music.  Reality Hackers #6 (Winter
1988) p. 27.  152.
_____.  1988.  THE CONTROLLED SUBSTANCES ACT: A resource manual of the
current status of the federal drug laws.  383 pp., published in Lafayette,
California  94549  April 1988.  154
_____.  In press.  History of MDMA.  \fIIn\fR: S. Peroutka [ed.], MDMA:
"Ecstasy" and human neurotoxin?  Kluwer Academic Publishers, Norwell, MA,

------end forwarded message----------